Ascentage releases results from multiple clinical studies of its lead drug candidates
These abstracts report on the company's three lead drug candidates, including olverembatinib
These abstracts report on the company's three lead drug candidates, including olverembatinib
Profit Before Tax is Rs. 220 crore, registering a commendable 64% growth
Updated results from the four studies will be presented in Oral Reports or Posters at the ASCO Annual Meeting
The acquisition is immediately accretive and creates a compelling, single-stop, multi-continent partner for biopharma companies
Acquisition will advance Merck’s integrated offering for viral vector manufacturing
Operationally ready by 2029, it will be the Company’s first-ever facility to cover the full manufacturing process for ADCs
Launch of 20 new medicines expected by 2030
Annapurna will lead the company in India ensuring patient access to its highly innovative medicines and vaccines
New data for Tezspire and Breztri demonstrate AstraZeneca’s innovation and commitment to transform care in COPD
Subscribe To Our Newsletter & Stay Updated